Cox J D, Kline R W
Int J Radiat Oncol Biol Phys. 1983 Mar;9(3):299-303. doi: 10.1016/0360-3016(83)90287-0.
Serial biopsies of the prostate after high dose external irradiation for adenocarcinoma show a gradual disappearance of the neoplastic cells. With such treatment, results of the biopsies do not have any short term prognostic significance. However, positive biopsies 12 months or more after treatment are reputed to be an unfavorable sign for long-term survival. From August, 1970 through February, 1974, 46 consecutive patients with locally advanced (Stage III, C, or T3 and T4) adenocarcinoma of the prostate underwent external irradiation with 2 MV X rays or cobalt-60 teletherapy. The technique included parallel, opposed, 14 X 14 cm anterior and posterior fields, and a 10 X 14 cm perineal field. The center of the prostate received a total dose of 70 Gy in 30-37 fractions in 43 to 56 days. Details of the dosimetry reveal inhomogeneity of the dose of +/- 7% within an enlarged prostate. With a median follow-up of 8 years, the actuarial survival rates, uncorrected for death from intercurrent disease, are 69% at 5 years and 49% at 10 years. Biopsies of the prostate 12 months or more after treatment were available from 31 patients: 19 had one or more positive biopsies and 12 had consistently negative biopsies; the survival curves are identical for those with and those without positive biopsies. Prostatic biopsies obtained 24 months or more after treatment were available from 21 patients: 10 had positive and 11 had negative biopsies; the survival curves are identical for those with and without residual cancer cells. Following adequate irradiation of patients with locally advanced adenocarcinoma of the prostate, the results of biopsies obtained one or two years after treatment do not predict long-term survival.
对前列腺腺癌进行高剂量外照射后进行的系列活检显示,肿瘤细胞逐渐消失。采用这种治疗方法,活检结果没有任何短期预后意义。然而,治疗后12个月或更长时间的阳性活检被认为是长期生存的不良迹象。从1970年8月到1974年2月,46例连续的局部晚期(III期、C期或T3和T4期)前列腺腺癌患者接受了2兆伏X射线或钴-60远距离治疗的外照射。技术包括平行相对的14×14厘米前后野和一个10×14厘米会阴部野。前列腺中心在43至56天内分30 - 37次接受了70戈瑞的总剂量。剂量测定细节显示,在增大的前列腺内剂量不均匀性为±7%。中位随访8年,未校正并发疾病死亡情况的精算生存率在5年时为69%,在10年时为49%。31例患者有治疗后12个月或更长时间的前列腺活检结果:19例有一次或多次阳性活检,12例活检一直为阴性;有阳性活检和无阳性活检患者的生存曲线相同。21例患者有治疗后24个月或更长时间的前列腺活检结果:10例为阳性,11例为阴性;有残留癌细胞和无残留癌细胞患者的生存曲线相同。对局部晚期前列腺腺癌患者进行充分照射后,治疗后一两年获得的活检结果不能预测长期生存。